Sunday, July 6, 2025
  • Login
CEO North America
  • Home
  • News
    • Business
    • Entrepreneur
    • Industry
    • Innovation
    • Management & Leadership
  • CEO Interviews
  • Opinion
  • Technology
  • Environment
  • CEO Life
    • Art & Culture
    • Food
    • Health
    • Travel
No Result
View All Result
  • Home
  • News
    • Business
    • Entrepreneur
    • Industry
    • Innovation
    • Management & Leadership
  • CEO Interviews
  • Opinion
  • Technology
  • Environment
  • CEO Life
    • Art & Culture
    • Food
    • Health
    • Travel
No Result
View All Result
CEO North America
No Result
View All Result

CEO North America > News > Landmark trial shows potential for psychedelic drugs to treat mental illness

Landmark trial shows potential for psychedelic drugs to treat mental illness

in News
- Landmark trial shows potential for psychedelic drugs to treat mental illness
Share on LinkedinShare on WhatsApp

New results from a clinical trial using MDMA to treat post-traumatic stress disorder showed the promise of a stigmatized drug to treat mental illness.

Drugs such as psilocybin and MDMA are rising in profile as mental illness treatment options after results from a phase 3 trial of MDMA combined with talk therapy for post-traumatic stress disorder showed impressive results, according to researchers.

“This is a pivotal event,” said Elemer Piros, a biotech analyst at Roth Capital Partners who covers the emerging alternative mental health treatment space. “It may not seem humongous, but it is one of the best and most rigorously executed trials in the space.”

The results of the MDMA study, whose senior author is Rick Doblin, founder and executive director of the Multidisciplinary Association for Psychedelic Studies, are expected to be published in the journal Nature Medicine on Monday and FDA approval could come by 2023, according to The New York Times.

A recent Imperial College London study of psilocybin use in depression reported in The New England Journal of Medicine also produced positive results.

In 2019, 51.5 million adults were living with a mental illness in the U.S., and the number of people suffering and drug costs, are projected to grow in the years ahead, with Covid-19 compounding mental health issues globally.

Tags: Mental illnesspsychedelic drugs

Related Posts

Paramount CEO explains why company paid Trump millions in 60 Minutes settlement
News

Paramount CEO explains why company paid Trump millions in 60 Minutes settlement

SAS CEO announces Air France–KLM to become majority owner
News

SAS CEO announces Air France–KLM to become majority owner

- Trump sends letter warning of 70% tariffs
News

Trump sends letter warning of 70% tariffs

Constellation CEO attributes beer sales decline to immigration crackdown
News

Constellation CEO attributes beer sales decline to immigration crackdown

China “strongly opposes” chip controls
News

Trump lifts chip restrictions on China

House on track for deadline after all-nighter
News

House on track for deadline after all-nighter

Hyundai and Kia to adopt Tesla EV chargers
News

Tesla stock rises as company reports steep sales decline

‘Big Beautiful Bill’ Medicaid cuts could leave millions uninsured
News

‘Big Beautiful Bill’ Medicaid cuts could leave millions uninsured

Del Monte Foods files for bankruptsy
News

Del Monte Foods files for bankruptsy

US job availability drops to new two-year low
News

Jobs report shows unexpected increase

No Result
View All Result

Recent Posts

  • What makes the Royal Edinburgh Military Tattoo so special?
  • Beyond the Machine: Why Human-Made Art Matters More in the Age of AI
  • 7 Benefits of High Intensity Interval Training
  • Paramount CEO explains why company paid Trump millions in 60 Minutes settlement
  • SAS CEO announces Air France–KLM to become majority owner

Archives

Categories

  • Art & Culture
  • Business
  • CEO Interviews
  • CEO Life
  • Editor´s Choice
  • Entrepreneur
  • Environment
  • Food
  • Health
  • Highlights
  • Industry
  • Innovation
  • Issues
  • Management & Leadership
  • News
  • Opinion
  • PrimeZone
  • Printed Version
  • Technology
  • Travel
  • Uncategorized

Meta

  • Log in
  • Entries feed
  • Comments feed
  • WordPress.org

  • CONTACT
  • GENERAL ENQUIRIES
  • ADVERTISING
  • MEDIA KIT
  • DIRECTORY
  • TERMS AND CONDITIONS

Advertising –
advertising@ceo-na.com

110 Wall St.,
3rd Floor
New York, NY.
10005
USA
+1 212 432 5800

Avenida Chapultepec 480,
Floor 11
Mexico City
06700
MEXICO

  • News
  • CEO Interviews
  • Opinion
  • Technology
  • Environment
  • CEO Life

  • CONTACT
  • GENERAL ENQUIRIES
  • ADVERTISING
  • MEDIA KIT
  • DIRECTORY
  • TERMS AND CONDITIONS

Advertising –
advertising@ceo-na.com

110 Wall St.,
3rd Floor
New York, NY.
10005
USA
+1 212 432 5800

Avenida Chapultepec 480,
Floor 11
Mexico City
06700
MEXICO

CEO North America © 2024 - Sitemap

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Home
  • News
    • Business
    • Entrepreneur
    • Industry
    • Innovation
    • Management & Leadership
  • CEO Interviews
  • Opinion
  • Technology
  • Environment
  • CEO Life
    • Art & Culture
    • Food
    • Health
    • Travel

© 2025 JNews - Premium WordPress news & magazine theme by Jegtheme.